Xenetic Biosciences (XBIO) Investor presentation summary

Technology platform and scientific rationale

• Focus on DNase I enzyme to target Neutrophil Extracellular Traps (NETs), which promote tumor growth, metastasis, and therapy resistance.

• DNase I eliminates NETs, exposing cancer cells to immune attack and reducing resistance to chemotherapy and immunotherapy.

• NETs contribute to immunosuppression, inflammation, and metastatic niche formation in the tumor microenvironment.

• Systemic DNase I can be co-administered with chemotherapy or immune checkpoint inhibitors to enhance antitumor effects.

• DNase I also improves the side effect profile of chemotherapies by reducing NET-driven inflammation and vascular injury.

Preclinical evidence and pipeline

• Preclinical models show DNase I enhances efficacy of PD-1 blockade and chemotherapy, reducing tumor growth and metastasis.

• DNase I monotherapy and in combination with checkpoint inhibitors or CAR T cells reduces metastatic burden in multiple cancer models.

• DNase I-armored CAR T cells maintain cytotoxic function and secrete DNase I, overcoming physical and immunosuppressive barriers in solid tumors.

• Proof-of-concept studies demonstrate improved survival and tumor control with DNase I-enhanced CAR T therapies.

• Pipeline includes systemic DNase I for pancreatic carcinoma, solid tumors, and hematological cancers, with investigator-initiated studies underway.

Clinical development and market opportunity

• Planned Phase 1 study will evaluate IV DNase I in advanced solid tumors, with dose escalation and expansion cohorts.

• Study will combine DNase I with chemotherapy for pancreatic cancer and with immunotherapy for other solid tumors.

• Pancreatic carcinoma targeted due to high unmet need, poor survival rates, and a projected $5.8B market by 2030.

• Success in pancreatic cancer defined as ORR > 50% or PFS > 9 months, exceeding current standards.

• Broad application potential across multiple solid tumor types, with ~1.9 million new cases annually in the U.S.